Genmab A/S (GNMSF) Gross Margin (2024 - 2026)
Genmab A's (GNMSF) quarterly Gross Margin came in at 92.75% in Q1 2026, down 138.0% YoY from 244.07% in Q1 2025, and down 1.44% on a QoQ basis from 94.1% in Q3 2025.
Genmab A/S (GNMSF) Gross Margin (2024 - 2026) Analysis & Trends
Genmab A (GNMSF) has 3 years of Gross Margin data on file, last reported at 92.75% in Q1 2026.
- Quarterly Gross Margin fell 138.0% year-over-year to 92.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 93.86% (down 167.0% YoY) and the FY2025 annual result came in at 93.6%, down 182.0% from the prior year.
- Gross Margin retreated to 92.75% in Q1 2026, from 94.1% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 96.02% in Q2 2024 to a low of 92.75% in Q1 2026.
- A 3-year average of 94.59% and a median of 94.13% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2025 — Gross Margin sank 206 bps — and 2026, when it plunged 138 bps.
- Tracing GNMSF's Gross Margin over 3 years: stood at 95.68% in 2024, then decreased by 2 bps to 94.1% in 2025, then slipped by 1 bps to 92.75% in 2026.
- The last three Gross Margin figures came in at 92.75% (Q1 2026), 94.1% (Q3 2025), and 93.96% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.73% |
| Mar 31, 2026 | 92.75% |
| Sep 30, 2025 | 94.10% |
| Jun 30, 2025 | 93.96% |
| Mar 31, 2025 | 94.13% |
| Sep 30, 2024 | 95.68% |
| Jun 30, 2024 | 96.02% |
| Mar 31, 2024 | 95.52% |